Early Norepinephrine Treatment with Rapid Dose Changes for Adults with Septic Shock A Multicenter Randomized Study to Improve Survival and Recovery

What this Trial Is About

Researchers are evaluating whether starting norepinephrine early with rapid dose adjustments can improve outcomes in adults with septic shock. The trial focuses on reducing 28-day mortality, speeding up shock control, and minimizing fluid needs without raising treatment-related side effects. It compares early norepinephrine use to standard treatment with delayed norepinephrine as needed. Participants will receive either norepinephrine or a placebo infusion within one hour of septic shock diagnosis. The norepinephrine starts at 0.05 mcgkgmin and is adjusted every 15 minutes based on blood pressure, with a maximum dose of 0.15 mcgkgmin. Both groups have rescue norepinephrine available if necessary. Limb ischemia and vital signs are closely monitored for 24 hours during the infusion. Throughout the study, participants receive standard sepsis care including fluids, antibiotics, and organ support. Researchers will monitor clinical outcomes and safety for up to 28 days. Key measures include survival at 28 days, time to shock control, and durations of intensive care, hospital stay, mechanical ventilation, and vasopressor therapy. Safety assessments focus on adverse events like cardiac arrhythmias and pulmonary edema.

Early Norepinephrine Administration and Rapid Dose Adjustment